Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2023

20-07-2023 | Ceftriaxone | Original Article

High carriage rate of extended‐spectrum β‐lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation

Authors: Chien Chuang, Kuei-Chuan Lee, Yen-Po Wang, Pei-Chang Lee, Tien-En Chang, Yi-Hsiang Huang, Yi-Tsung Lin, Ming-Chih Hou

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2023

Login to get access

Abstract

The safety of fecal microbiota transplantation (FMT) has been highlighted by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli bacteremia transmitted from donors and acquisition of diarrheagenic E. coli (Shiga toxin-producing E. coli (STEC) and enteropathogenic E. coli (EPEC)) via FMT. The use of donor screening criteria to lower the risk of pathogen transmission via FMT is essential. This study aimed to demonstrate the outcomes of our strict donor screening program. This study was conducted at our FMT center between January 2019 and June 2022. Our donor screening program included an initial questionnaire and subsequent blood and stool testing. We further used selective culture for third-generation cephalosporin-resistant (3GCR) Enterobacterales and multiplex PCR to detect diarrheagenic E. coli in stools. The resistance mechanisms and sequence type of 3GCR Enterobacterales were determined. A total of 742 individuals were assessed, and 583 participants (78.6%) were excluded after questionnaire. Of the remaining 159 participants undergoing stool and blood tests, 37 participants were finally qualified (5.0%, 37/742). A high fecal carriage rate of ESBL-producing Enterobacterales (35.2%, 56/159), including E. coli (n=53) and Klebsiella pneumoniae (n=5), and diarrheagenic E. coli (31.4%, 50/159), including EPEC (n=41), enteroaggregative E. coli (n=11), enterotoxigenic E. coli (n=4), and STEC (n=1), was noted. CTX-M-79 and CTX-M-15 were dominant in E. coli and K. pneumoniae, respectively. The sequence types of the ESBL-producing strains were diverse. The screening for 3GCR Enterobacterales and diarrheagenic E. coli in stool is necessary. Our findings also support the effectiveness of multiplex PCR panels in FMT donor screening programs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hvas CL, Dahl Jørgensen SM, Jørgensen SP et al (2019) Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 156:1324–32.e3CrossRefPubMed Hvas CL, Dahl Jørgensen SM, Jørgensen SP et al (2019) Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 156:1324–32.e3CrossRefPubMed
2.
go back to reference van Prehn J, Reigadas E, Vogelzang EH et al (2021) European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 27(Suppl 2):S1–S21CrossRefPubMed van Prehn J, Reigadas E, Vogelzang EH et al (2021) European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 27(Suppl 2):S1–S21CrossRefPubMed
3.
go back to reference Bakken JS, Borody T, Brandt LJ et al (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9(12):1044–9CrossRefPubMedPubMedCentral Bakken JS, Borody T, Brandt LJ et al (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9(12):1044–9CrossRefPubMedPubMedCentral
4.
go back to reference DeFilipp Z, Bloom PP, Torres Soto M et al (2019) Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 381:2043–2050CrossRefPubMed DeFilipp Z, Bloom PP, Torres Soto M et al (2019) Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 381:2043–2050CrossRefPubMed
5.
go back to reference Zellmer C, Sater MRA, Huntley MH et al (2021) Shiga toxin-producing E. coli transmission via fecal microbiota transplant. Clin Infect Dis 72:e876–e880CrossRefPubMed Zellmer C, Sater MRA, Huntley MH et al (2021) Shiga toxin-producing E. coli transmission via fecal microbiota transplant. Clin Infect Dis 72:e876–e880CrossRefPubMed
9.
go back to reference Lin TC, Hung YP, Ko WC et al (2019) Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: establishment and implementation. J Microbiol Immunol Infect 52:841–50CrossRefPubMed Lin TC, Hung YP, Ko WC et al (2019) Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: establishment and implementation. J Microbiol Immunol Infect 52:841–50CrossRefPubMed
10.
go back to reference Woodworth MH, Neish EM, Miller NS et al (2017) Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Microbiol 55:1002–10CrossRefPubMedPubMedCentral Woodworth MH, Neish EM, Miller NS et al (2017) Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Microbiol 55:1002–10CrossRefPubMedPubMedCentral
11.
go back to reference Ianiro G, Porcari S, Bibbò S et al (2021) Donor program for fecal microbiota transplantation: a 3-year experience of a large-volume Italian stool bank. Dig Liver Dis 53:1428–32CrossRefPubMed Ianiro G, Porcari S, Bibbò S et al (2021) Donor program for fecal microbiota transplantation: a 3-year experience of a large-volume Italian stool bank. Dig Liver Dis 53:1428–32CrossRefPubMed
12.
go back to reference Clinical and Laboratory Standards Institute (2021) M100-S31. Performance standards for antimicrobial susceptibility testing: 31th informational supplement. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (2021) M100-S31. Performance standards for antimicrobial susceptibility testing: 31th informational supplement. CLSI, Wayne, PA
13.
go back to reference Ma L, Lu PL, Siu LK et al (2013) Molecular typing and resistance mechanisms of imipenem-non-susceptible Klebsiella pneumoniae in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. J Med Microbiol 62:101–7CrossRefPubMed Ma L, Lu PL, Siu LK et al (2013) Molecular typing and resistance mechanisms of imipenem-non-susceptible Klebsiella pneumoniae in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. J Med Microbiol 62:101–7CrossRefPubMed
14.
go back to reference Chen PA, Hung CH, Huang PC et al (2016) Characteristics of CTX-M extended-spectrum β-lactamase-producing Escherichia coli strains isolated from multiple rivers in southern Taiwan. Appl Environ Microbiol 82:1889–97CrossRefPubMedPubMedCentral Chen PA, Hung CH, Huang PC et al (2016) Characteristics of CTX-M extended-spectrum β-lactamase-producing Escherichia coli strains isolated from multiple rivers in southern Taiwan. Appl Environ Microbiol 82:1889–97CrossRefPubMedPubMedCentral
15.
16.
go back to reference Svenungsson B, Lagergren A, Ekwall E et al (2000) Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin Infect Dis 30:770–8CrossRefPubMed Svenungsson B, Lagergren A, Ekwall E et al (2000) Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin Infect Dis 30:770–8CrossRefPubMed
17.
go back to reference Craven LJ, Nair Parvathy S, Tat-Ko J et al (2017) Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases. Open Forum Infect Dis 4:ofx243CrossRefPubMedPubMedCentral Craven LJ, Nair Parvathy S, Tat-Ko J et al (2017) Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases. Open Forum Infect Dis 4:ofx243CrossRefPubMedPubMedCentral
18.
go back to reference Kassam Z, Dubois N, Ramakrishna B et al (2019) Donor screening for fecal microbiota transplantation. N Engl J Med 381:2070–2CrossRefPubMed Kassam Z, Dubois N, Ramakrishna B et al (2019) Donor screening for fecal microbiota transplantation. N Engl J Med 381:2070–2CrossRefPubMed
19.
go back to reference Terveer EM, Vendrik KE, Ooijevaar RE et al (2020) Faecal microbiota transplantation for Clostridioides difficile infection: four years’ experience of the Netherlands Donor Feces Bank. United Eur Gastroenterol J 8:1236–1247CrossRef Terveer EM, Vendrik KE, Ooijevaar RE et al (2020) Faecal microbiota transplantation for Clostridioides difficile infection: four years’ experience of the Netherlands Donor Feces Bank. United Eur Gastroenterol J 8:1236–1247CrossRef
20.
go back to reference van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–15CrossRefPubMed van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–15CrossRefPubMed
21.
go back to reference Paramsothy S, Borody TJ, Lin E et al (2015) Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 21:1600–6CrossRefPubMed Paramsothy S, Borody TJ, Lin E et al (2015) Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 21:1600–6CrossRefPubMed
22.
go back to reference Costello SP, Tucker EC, La Brooy J et al (2016) Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62:908–14CrossRefPubMed Costello SP, Tucker EC, La Brooy J et al (2016) Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62:908–14CrossRefPubMed
23.
go back to reference Terveer EM, van Beurden YH, Goorhuis A et al (2017) How to: establish and run a stool bank. Clin Microbiol Infect 23:924–30CrossRefPubMed Terveer EM, van Beurden YH, Goorhuis A et al (2017) How to: establish and run a stool bank. Clin Microbiol Infect 23:924–30CrossRefPubMed
24.
go back to reference Zhang S, Chen Q, Kelly CR et al (2022) Donor screening for fecal microbiota transplantation in China: evaluation of 8483 candidates. Gastroenterology 162:966-968.e3CrossRefPubMed Zhang S, Chen Q, Kelly CR et al (2022) Donor screening for fecal microbiota transplantation in China: evaluation of 8483 candidates. Gastroenterology 162:966-968.e3CrossRefPubMed
25.
go back to reference Yau YK, Mak WYJ, Lui NSR et al (2021) High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong Kong. United Eur Gastroenterol J 9:1027–38CrossRef Yau YK, Mak WYJ, Lui NSR et al (2021) High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong Kong. United Eur Gastroenterol J 9:1027–38CrossRef
26.
go back to reference Seo HS, Chin HS, Kim YH et al (2021) Laboratory aspects of donor screening for fecal microbiota transplantation at a Korean fecal microbiota bank. Ann Lab Med 41:424–8CrossRefPubMedPubMedCentral Seo HS, Chin HS, Kim YH et al (2021) Laboratory aspects of donor screening for fecal microbiota transplantation at a Korean fecal microbiota bank. Ann Lab Med 41:424–8CrossRefPubMedPubMedCentral
27.
go back to reference Vendrik KEW, Terveer EM, Kuijper EJ et al (2021) Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infect Dis 21:711–21CrossRefPubMed Vendrik KEW, Terveer EM, Kuijper EJ et al (2021) Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. Lancet Infect Dis 21:711–21CrossRefPubMed
28.
go back to reference Bezabih YM, Bezabih A, Dion M et al (2022) Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist 4:dlac048CrossRefPubMedPubMedCentral Bezabih YM, Bezabih A, Dion M et al (2022) Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist 4:dlac048CrossRefPubMedPubMedCentral
29.
go back to reference Huang YS, Lai LC, Chen YA et al (2020) Colonization with multidrug-resistant organisms among healthy adults in the community setting: prevalence, risk factors, and composition of gut microbiome. Front Microbiol 11:1402CrossRefPubMedPubMedCentral Huang YS, Lai LC, Chen YA et al (2020) Colonization with multidrug-resistant organisms among healthy adults in the community setting: prevalence, risk factors, and composition of gut microbiome. Front Microbiol 11:1402CrossRefPubMedPubMedCentral
30.
go back to reference Chung HC, Lai CH, Lin JN et al (2012) Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 56:618–22CrossRefPubMedPubMedCentral Chung HC, Lai CH, Lin JN et al (2012) Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 56:618–22CrossRefPubMedPubMedCentral
31.
go back to reference Tsai WL, Hung CH, Chen HA et al (2018) Extended-spectrum β-lactamase-producing Escherichia coli bacteremia: comparison of pediatric and adult populations. J Microbiol Immunol Infect 51:723–31CrossRefPubMed Tsai WL, Hung CH, Chen HA et al (2018) Extended-spectrum β-lactamase-producing Escherichia coli bacteremia: comparison of pediatric and adult populations. J Microbiol Immunol Infect 51:723–31CrossRefPubMed
33.
go back to reference Decker BK, Lau AF, Dekker JP et al (2018) Healthcare personnel intestinal colonization with multidrug-resistant organisms. Clin Microbiol Infect 24:82.e1-82.e4CrossRefPubMed Decker BK, Lau AF, Dekker JP et al (2018) Healthcare personnel intestinal colonization with multidrug-resistant organisms. Clin Microbiol Infect 24:82.e1-82.e4CrossRefPubMed
34.
go back to reference Campos-Madueno EI, Moradi M, Eddoubaji Y et al (2023) Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis 42(3):229–254CrossRefPubMedPubMedCentral Campos-Madueno EI, Moradi M, Eddoubaji Y et al (2023) Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis 42(3):229–254CrossRefPubMedPubMedCentral
Metadata
Title
High carriage rate of extended‐spectrum β‐lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation
Authors
Chien Chuang
Kuei-Chuan Lee
Yen-Po Wang
Pei-Chang Lee
Tien-En Chang
Yi-Hsiang Huang
Yi-Tsung Lin
Ming-Chih Hou
Publication date
20-07-2023

Other articles of this Issue 9/2023

European Journal of Clinical Microbiology & Infectious Diseases 9/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine